GSK Plc: Gepotidacin Shows Non-inferiority To Nitrofurantoin In EAGLE-2 And EAGLE-3 Phase III Trials

(RTTNews) - GSK plc (GSK, GSK.L) reported positive results from the EAGLE-2 and EAGLE-3 phase III trials for gepotidacin, an investigational oral antibiotic for uncomplicated urinary tract infections in female adults and adolescents. In the EAGLE-2 and EAGLE-3 phase III trials, gepotidacin showed non-inferiority to nitrofurantoin, an existing first-line treatment for uUTI. Also, in the EAGLE-3 phase III trial, gepotidacin showed statistically significant superiority versus nitrofurantoin.

Gepotidacin demonstrated consistent efficacy compared to nitrofurantoin in key subgroups.

For More Such Health News, visit rttnews.com.